Curosurf

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This product helps improve lung function and oxygenation, supporting critical care for newborns.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs lack sufficient surfactant, a substance that keeps the air sacs open. By administering Curosurf, healthcare providers aim to improve lung compliance and reduce the work of breathing. The therapy is typically administered via endotracheal tube, directly into the lungs.

Curosurf works by replacing the natural surfactant in the lungs, which helps to reduce surface tension and prevent the collapse of alveoli. This can lead to improved oxygenation and reduced need for mechanical ventilation. Common effects include stabilization of lung function and improved respiratory rates in premature infants.

Curosurf should be administered by trained healthcare professionals in a controlled medical setting. It is essential to monitor the infant closely for any adverse reactions. Proper handling and storage are crucial to maintain the efficacy of the product. Always follow the guidelines provided by the manufacturer and healthcare providers.

Curosurf is generally used in a controlled medical environment where interactions with other medications are carefully managed. However, it is important to inform healthcare providers about any other treatments the infant is receiving to avoid potential complications. Always consult with a healthcare professional before administering any additional therapies.